FDA Rejects Canagliflozin/Metformin Combo for Now

Miriam E. Tucker

January 09, 2014

(Corrected January 15, 2014) The US Food and Drug Administration (FDA) has informed Janssen Research & Development that it needs more information before the fixed-dose canagliflozin/metformin combination can be approved for the treatment of type 2 diabetes.

The company announced last month that it had received a "complete response letter" from the US agency asking for more data to support comparability of the proposed dosing of the fixed-dose combination with that of once-daily canagliflozin (Invokana).

"Janssen believes it can supply this information based on available clinical data from the comprehensive phase 3 clinical development program for canagliflozin," the company said in a statement.

Approved by the FDA as a single agent in March 2013, canagliflozin is an oral inhibitor of the sodium glucose cotransporter 2 (SGLT2), blocking resorption of glucose by the kidney and thereby promoting glycosuria with a consequent lowering of both blood glucose and body weight. Metformin is a first-line oral medication that reduces hepatic glucose production and is the most commonly used therapeutic in type 2 diabetes.

According to the company statement, "If approved, the canagliflozin and metformin fixed-dose combination could provide convenience for patients who may benefit from the 2 diabetes medications in 1 tablet."

The FDA has just approved a second SGLT2 inhibitor, dapagliflozin(Farxiga, AstraZeneca/Bristol-Myers Squibb) at its second attempt to gain US clearance.

The combination of dapagliflozin/metformin (Xigduo , AstraZeneca/Bristol-Myers Squibb) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of type 2 diabetes in the European Union in November 2013, and subsequent approval is usually a formality within a couple of months.

Canagliflozin was approved in the European Union in November, where it is also marketed as Invokana; it is also available in Australia.

An earlier version of this story incorrectly stated that canagliflozin was not approved in the European Union.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: